<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631097</url>
  </required_header>
  <id_info>
    <org_study_id>AV-951-12-118</org_study_id>
    <nct_id>NCT01631097</nct_id>
  </id_info>
  <brief_title>A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function</brief_title>
  <official_title>A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics,
      safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of
      hepatic impairment and normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from Hour 0 to the last measurable concentration (AUC0 t)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (λz)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance (CL/F)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>pre-dose, 1, 3, 5, 7, 10, 12, 18, 24, 36, 48, 96, 168, 336, and 504 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>Baseline and End of Study Visit (Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physical examinations</measure>
    <time_frame>Baseline and End of Study Visit (Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hematology including coagulation assessments</measure>
    <time_frame>Baseline and End of Study Visit (Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in chemistry assessments</measure>
    <time_frame>Baseline and End of Study Visit (Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urinalysis assessments</measure>
    <time_frame>Baseline and End of Study Visit (Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in thyroid function tests</measure>
    <time_frame>Baseline and End of Study Visit (Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiograms</measure>
    <time_frame>Baseline and End of Study Visit (Day 30)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hepatic Impairment</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivozanib hydrochloride</intervention_name>
    <description>Single oral capsule 1.5 mg tivozanib hydrochloride</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18 to 38 kg/m2

          -  diagnosis of chronic or stable hepatic insufficiency, with a Child-Pugh classification
             scores of mild, moderate or severe.

        Exclusion Criteria:

          -  Current or previous history of hepatic carcinoma, hepatorenal syndrome, portacaval
             shunt surgery, significant hepatic encephalopathy, severe ascites, or pleural effusion

          -  Currently undergoing dialysis

          -  Poor peripheral venous access

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

